Qilu Pharmaceutical's Trastuzumab Biosimilar (QL1701) Approved in China for HER2-Positive Metastatic Breast Cancer

Jul 05, 2024 16:08 CST Updated 16:08

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

On July 5, according to the NMPA official website, Qilu Pharmaceutical's trastuzumab for injection was approved for marketing in China.

Source: NMPA Official Website

According to Qilu News, the Trastuzumab Monoclonal Antibody Injection (referred to as: QL1701) developed by Qilu Pharmaceutical is a potential biosimilar to Herceptin®, applicable for the treatment of HER2-positive metastatic breast cancer. Preliminary studies have shown that QL1701 is highly consistent with Herceptin®. According to the Insight database, QL1701 has conducted a Phase III clinical trial in China for first-line treatment of HER2-positive metastatic breast cancer patients, which has been completed (registration number:NCT05629949/CTR20192189）。

NCT05629949/CTR20192189 Trial Historical Timeline

Source: Insight Database Web Version

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Editor：Hebe

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn

Diversified functions, traceable data……

Insight Database Web Version Awaits Your Experience

Click to read the original text,ImmediatelyUnlock！